Torresan, S, Torres, CSD, Caramella, C, Ambrosini, P, Gomez-Randulfe, I, Monaca, F, Ribera, A, Goudsmit, A, Michelini, A, Segui, V, Insa, A, Martorell, PM, Romero-Sola, G, Caro-Consuegra, R, Mirallas, O, Priano, I, Valdivia, A, Masfarré, L, Iranzo, P, Martinez-Marti, A, Cedres, S, Catot, S, Sequeira, T, Callejo, A, Bearz, A, Barba, A, Antoñanzas, M, Sais, E, Baena, J, Brandao, M, Mosteiro, M, Vilariño, N, Gambardella, V, Moran, T, Occhipinti, M, Califano, R, Pardo, N, Felip, E, Rocha, P. Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

De Castro, J, Bernabé, R, Escudero, V, Gutiérrez, F, Majem, M, Gordo, R, Arroyo, I, Arranz, S, Collado, R. Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Sanchez, AYC, Bustillos, A, Herraez-Baranda, L, Barata, T, Young, F, Majem, M. IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Wang, M, Jänne, PA, Doucet, L, Fan, Y, Lv, D, Sun, M, Huang, D, Greillier, L, Planchard, D, Hong, Q, Mazieres, J, Felip, E, Li, X, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Ferreira, BP, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, R, Zalcman, G, Carpeño, JD, Di Noia, V, Parra, HS, Streich, G, Lee, D, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquín, AB, Liu, G, Antonuzzo, L, Fernandez-Hinojal, G, Le, X, Zheng, L, Yang, JCH. A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).